The collboration brings together four initiatives designed to address different barriers to ALS research. The ALS Society of ...

Two proteins in the panel, neurofilament light chain (NfL) and neurofilament heavy chain (NEFH), are well-established markers of nerve damage in ALS. Two others, pTau-181 and VEGFA, have also been ...

Lily Sander, national ambassador for the Muscular Dystrophy Association (MDA), hit on those themes in the opening talk at MDA ...

The experimental treatment AP-101 may help ALS patients preserve body weight, trial data show. Preservation of body weight is ...

ALS.Community has launched a new free online platform to help people with amyotrophic lateral sclerosis (ALS), their families ...

So many things in this world don’t have a cure, but compassion and care help.

Amyotrophic lateral sclerosis (ALS) is a rare, progressive neurological disease caused by the death of nerve cells that control voluntary movement. ALS statistics from the Centers for Disease Control ...

Fatigue in amyotrophic lateral sclerosis (ALS) is common, affecting close to half of people living with the condition. It goes beyond simply feeling tired and can lead to deep exhaustion that makes ...

Kristin Neva is an author, mother of two, and caregiver for her husband, Todd, who was diagnosed with ALS in 2010 when he was 39 years old. Knowing they would need family support, they moved to Upper ...

Clene Nanomedicine has submitted an application to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of its experimental oral therapy CNM-Au8 for people with amyotrophic lateral ...

RAG-21, a therapy Ractigen Therapeutics is developing for amyotrophic lateral sclerosis (ALS) linked to mutations in the FUS gene, has been awarded orphan drug status by the U.S. Food and Drug ...